Vitiligo is believed to be an autoimmune condition where the body attacks its own healthy melanin-producing skin cells by mistake. It may be hereditary or triggered by a particular event like ...

Adding twice-weekly narrowband UVB phototherapy to oral ritlecitinib may enhance response to treatment of nonsegmental vitiligo. Dual treatment was well-tolerated with no new safety signals in ...

At week 24, the ritlecitinib plus nbUVB group saw a higher facial vitiligo severity change from baseline vs. the ritlecitinib-monotherapy group. Similar reductions were seen in body vitiligo severity.